Welcome to our dedicated page for CHINA INFRASTRUCTURE CONSTRUCTI news (Ticker: CHNC), a resource for investors and traders seeking the latest updates and insights on CHINA INFRASTRUCTURE CONSTRUCTI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CHINA INFRASTRUCTURE CONSTRUCTI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CHINA INFRASTRUCTURE CONSTRUCTI's position in the market.
China Infrastructure Construction Corp. (OTC: CHNC) has expanded its clinical research services to Latin America through a new partnership with QUIASMO, an IPS medical clinic in Bogotá, Colombia. This agreement allows CHNC to enhance its offerings in Puerto Rico and now Colombia, targeting pharmaceutical companies interested in conducting clinical research in these regions. The collaboration will leverage the expertise of Dr. John Jairo Carvajal at QUIASMO, facilitating crucial medical investigations and treatments across various therapeutic areas.
China Infrastructure Construction Corp. (OTC: CHNC) announced the departure of Elizabeth Hernandez from her roles as Chief Operating Officer and board member, effective July 28, 2021. To fill this vacancy, the company appointed Anne Marie Graham, previously Director of International Markets, to the Board of Directors. Graham brings valuable experience in corporate law and international partnerships, significantly contributing to CHNC's strategic alliances and growth. The management change aims to enhance the company's market role and profitability.
China Infrastructure Construction Corp. (OTC: CHNC), operating as Cannabis Bioscience International Holdings, is set to enhance its educational product distribution by introducing multilingual content in 15 languages within 30 to 45 days. This expansion aims to penetrate emerging markets, including Russia and China, potentially reaching 150 countries and 500 million customers worldwide. CHNC anticipates generating $1 million to $1.5 million in additional revenue for 2022 fueled by this strategy. The company also welcomes six new team members and plans to add more to support its growth objectives.
China Infrastructure Construction Corp. (OTC: CHNC) is seeking strategic partners to invest up to $3 million in its growth plans. The company aims to broaden its existing digital products and services, enhance staff from 60 to 250 by Q3 2022, and conduct research on cannabis benefits. CHNC also plans to establish a manufacturing facility for medical and nutraceutical products derived from cannabis. However, there is no guarantee that investments will be secured on favorable terms.
China Infrastructure Construction Corp. (CHNC) reported a remarkable 2,550% ROI for 2021, with share prices soaring from $0.0002 to $0.0053 over the year. This equates a $1,000 investment made on September 17, 2020, growing to $26,500 by September 17, 2021. Despite this achievement, executives underscore ongoing challenges that must be addressed to ensure stability and productivity in 2022. The company plans to enhance its operational focus and maintains a commitment to long-term growth amidst market volatility.
China Infrastructure Construction Corp. (CHNC) has enhanced its distribution strategy for educational digital content, now available on major platforms like Amazon, Walmart, and Barnes & Noble. This move follows a significant increase in its subscriber base from 50,000 to over 2 million across 109 countries. The company aims to provide comprehensive cannabis education through its platform, Pharmacology University, and has collaborated with 30 online educational companies. The digital products are offered in various languages, highlighting the company’s commitment to global outreach.
China Infrastructure Construction Corp. has announced a rebranding to Cannabis Bioscience International Holdings, reflecting its growing global operations in the cannabis sector. The company plans to file for a corporate name change and a new trading symbol (CHNC) within the next three months, pending the necessary regulatory approvals. This name change aligns with its international expansion strategy across Europe, Latin America, the Middle East, and the USA. The company aims to enhance its market presence through this rebranding initiative.
China Infrastructure Construction Corp. (OTC: CHNC) has announced a significant buyback of 4 billion shares, ensuring no dilution for current shareholders. The shares will be held in the company's treasury, reinforcing ownership consolidation. The company is also enhancing its educational initiatives, developing accredited programs for medical cannabis education. New partnerships with Colombian universities aim to expand their reach and promote cannabis as a medicinal option. CHNC remains committed to advancing the medical cannabis industry and exploring new educational avenues.
China Infrastructure Construction Corp. (OTC: CHNC) has undergone significant restructuring following its merger with Pharmacology University in December 2019. The company faced a daunting $1.84 million debt and minimal revenue of $259,737 in 2019. In 2020, CHNC eliminated debt and reported a 285% revenue increase. The company aims to expand its educational projects and recently launched Canna Law and Canna Med magazines to provide information on the cannabis industry. Additionally, CHNC opened the ALPHA Fertility & Sleep Center, focusing on sleep-related disorders and fertility issues.